Master Bond Debuts UV26DCMed Dual-Cure Adhesive

Why It Matters

The adhesive enables manufacturers to produce sterilizable, reusable medical devices faster and at lower cost, meeting stringent regulatory and sustainability demands.

Key Takeaways

• Dual‑cure adhesive combines UV and heat curing
• Handles repeated autoclave, EtO, glutaraldehyde sterilization
• Tensile strength up to 8,000 psi, Tg 170 °C
• Low viscosity enables automated high‑speed dispensing
• Meets ISO 10993‑5 non‑cytotoxicity for medical devices

Pulse Analysis

The medical device sector increasingly demands adhesives that survive harsh sterilization cycles without compromising performance. Master Bond’s UV26DCMed addresses this gap by offering a single‑component, dual‑cure system that first cures under UV light for rapid positioning and then completes polymerization with a heat bake. This combination eliminates the need for multi‑step processes while delivering consistent bond strength after steam autoclave, ethylene oxide, or hydrogen‑peroxide treatments. By meeting ISO 10993‑5 cytotoxicity standards, the adhesive aligns with regulatory expectations for reusable instruments such as syringes and fluid containers, and enables rapid prototyping cycles.

Beyond sterilization resilience, UV26DCMed offers a suite of mechanical and physical properties that simplify high‑volume production. Its low viscosity range of 500–3,500 cps ensures smooth flow through automated dispensing equipment, while the cured material exhibits tensile strengths of 6,000–8,000 psi and a modulus exceeding 750,000 psi. The high glass transition temperature of 160–170 °C and service window from –60 °F to +500 °F provide thermal stability for demanding applications. Electrical non‑conductivity and strong adhesion to metals, glass, plastics, and ceramics further broaden its use cases, making it suitable for aerospace‑grade medical equipment.

Adoption of UV26DCMed could accelerate the shift toward reusable, cost‑effective medical devices, a trend driven by sustainability pressures and reimbursement models. Manufacturers that integrate this adhesive can reduce inventory of multiple curing agents and lower cycle times, translating into higher throughput and lower labor costs. As regulatory bodies continue to tighten biocompatibility requirements, having a single, ISO‑compliant adhesive simplifies compliance documentation. Consequently, UV26DCMed positions itself as a strategic material for innovators seeking to balance performance, safety, and production efficiency. Future iterations may incorporate bio‑resorbable chemistries.